HC Wainwright Reiterates Buy Rating for Pyxis Oncology (NASDAQ:PYXS)

Key Points

• HC Wainwright reaffirmed a Buy rating on Pyxis Oncology with a $7 price target, implying 131.79% upside from the prior close. Analysts overall assign the stock a “Moderate Buy” consensus rating with a $7.50 average target.
• Pyxis Oncology opened at $3.02 and has a market capitalization of approximately $191.3 million, trading between a 52-week low of $1.03 and high of $5.55.
• The clinical-stage biotechnology company reported quarterly EPS of -$0.40, missing the consensus estimate of -$0.35; analysts expect a full-year loss of approximately $1.26 per share.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report)'s stock had its "buy" rating reaffirmed by stock analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $7.00 price objective on the stock. HC Wainwright's price target would indicate a potential upside of 131.79% from the stock's previous close.

Several other analysts have also recently weighed in on the stock. Wells Fargo & Company began coverage on shares of Pyxis Oncology in a report on Monday, August 3rd. They issued an "overweight" rating and a $12.00 price target on the stock. Weiss Ratings cut shares of Pyxis Oncology from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Tuesday, June 30th. Wedbush initiated coverage on shares of Pyxis Oncology in a research note on Tuesday, May 5th. They set an "outperform" rating and a $6.00 target price on the stock. Leerink Partners reduced their price target on shares of Pyxis Oncology from $9.00 to $7.00 and set an "outperform" rating on the stock in a research report on Thursday, July 2nd. Finally, Wall Street Zen downgraded shares of Pyxis Oncology from a "hold" rating to a "sell" rating in a research note on Saturday, May 16th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $7.50.

Pyxis Oncology Stock Performance

NASDAQ PYXS opened at $3.02 on Tuesday. The stock has a market cap of $191.32 million, a P/E ratio of -2.14 and a beta of 1.31. Pyxis Oncology has a fifty-two week low of $1.03 and a fifty-two week high of $5.55. The stock has a 50 day simple moving average of $2.58 and a two-hundred day simple moving average of $1.98.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last posted its earnings results on Thursday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.05). Sell-side analysts predict that Pyxis Oncology will post -1.26 earnings per share for the current year.

Hedge Funds Weigh In On Pyxis Oncology

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Renaissance Technologies LLC boosted its holdings in shares of Pyxis Oncology by 22.0% during the 1st quarter. Renaissance Technologies LLC now owns 888,680 shares of the company's stock valued at $1,297,000 after buying an additional 160,300 shares in the last quarter. J. Derek Lewis & Associates Inc. bought a new position in shares of Pyxis Oncology in the 4th quarter worth about $61,000. XTX Topco Ltd increased its stake in shares of Pyxis Oncology by 1,533.0% in the 4th quarter. XTX Topco Ltd now owns 289,033 shares of the company's stock worth $332,000 after acquiring an additional 271,334 shares in the last quarter. Toronto Dominion Bank purchased a new position in Pyxis Oncology during the 4th quarter valued at about $86,000. Finally, Quadrature Capital Ltd bought a new stake in Pyxis Oncology during the fourth quarter worth about $116,000. Hedge funds and other institutional investors own 39.07% of the company's stock.

Pyxis Oncology Company Profile

Pyxis Oncology NASDAQ: PYXS is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company's platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source